Metagenomi Therapeutics, Inc.
MGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Metagenomi Therapeutics, Inc. focuses on Biotechnology services and products. Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. Valued at $44.2M, MGX is a micro-cap name in its sector. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
Market Cap
$44.2M
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-0.64
EPS (TTM)
$-2.51
EPS (Fwd)
$-1.83
ROE
-60.6%
ROA
-28.2%
Cash
$120.7M
Total Debt
$37.7M
Free CF
-$51.0M
52W Change
-37.1%
Annual Financials
Cash vs Debt
Where MGX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, MGX finished 13.33% below its 150-day moving average ($1.35) and 18.75% below its 200-day moving average ($1.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MGX overbought or oversold?
At the September 2, 2026 close, MGX's RSI(14) was 38.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $120.7M in cash comfortably exceeding the $37.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$51.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -60.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $17.2M (2022) to $25.2M (2025), reflecting a 47% increase over the period.
The relatively low beta of 0.68 suggests MGX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, MGX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Metagenomi Therapeutics, Inc. and its sector.